Category: Policy / Pricing
PharmaSignal — Policy / Pricing
Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients
BioSpace
With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead for psychedelics.
Medicare obesity drug pilot extended after insurer pushback
Pharmaphorum
Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.
Italy leads the way on child genetic disease diagnosis
Pharmaphorum
A scheme to hasten the diagnosis of children with genetic disorders is achieving strong results and could be a template for national health systems.
Trump executive order lifts psychedelics biotechs
BioPharma Dive
Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more investable space.
RFK Jr. defends HHS tenure, 12% proposed budget cut
BioPharma Dive
Republicans largely praised the HHS secretary s track record during a marathon of House hearings last week, but some raised concerns about proposed budget cuts to the National Institutes of Health.
FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development
FDA
Since publishing roadmap last April, agency has successfully launched several key initiatives to replace animal testing with better alternatives
FDA Policy Tracker 2026: Psychedelics get a boost
BioSpace
A year of significant policy change at the FDA brought momentum and scrutiny into the new year.
Trump backs psychedelics for mental health in new executive order
Pharmaceutical Technology
Trump’s executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.
Trump signs order to hasten psychedelic medicine access
Pharmaphorum
Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients.
RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media
BioSpace
The pharma industry “own Congress, they own the media,” Health Secretary Robert F.
Trump names Erica Schwartz to fill leadership void at CDC
Pharmaphorum
Former Deputy Surgeon General Erica Schwartz could end months at the CDC without Senate-confirmed leadership if she becomes Director.
Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director
BioPharma Dive
If confirmed by the Senate, Schwartz could finally fill a void for an agency that s cycled through multiple leaders over the last year.
FDA accelerated approval path needs improvement, says ICER
Pharmaphorum
The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.
Most patients “won’t see benefit” with Alzheimer’s drugs
Pharmaphorum
A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts.
Scientists issue call to arms over antifungal resistance
Pharmaphorum
Infectious disease experts from around the world are calling for concerted action to combat a “silent surge” in resistance to antifungal drugs.
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders
BioPharma Dive
The newly published charter widens the required expertise to become an ACIP member and stresses vaccine safety.
NHS risks missing out on independent prescriber benefits
Pharmaphorum
Gaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report.
AbbVie tries a new approach in 340B programme battle
Pharmaphorum
AbbVie has opened a new front in the pharma industry’s efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun)
Drug Channels
This week, I’m rerunning some popular posts while we prepare for tomorrow’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead .